We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Beats on Q2 Earnings, Revenues
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment. JNJ also had issues with its consumer segment manufacturing facilities. Another headwind is unfavorable currency movement.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 2.13%. Estimates have also been revised upwards for 2016.
Currently, JNJ has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on second quarter earnings - the company reported EPS of $1.74 while our consensus called for EPS of $1.67.
Revenues Beat: Revenues were above expectations as well. Johnson & Johnson posted revenues of $18.5 billion, compared to our consensus estimate of $17.9 billion.
Ups Guidance: J&J upped its 2016 sales guidance to $71.5 billion - $72.2 billion (guidance provided with 1Q results: $71.2 billion to $71.9 billion) and earnings guidance to $6.63 - $6.73 per share (guidance provided with 1Q results: $6.53 - $6.68 per share). The Zacks Consensus Estimate for revenues and earnings currently stands at $71.6 billion and $6.60 per share, respectively.
Pre-Market Trading: Shares were up more than 3% in pre-market trading.
Check back later for our full write up on this JNJ earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Beats on Q2 Earnings, Revenues
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment. JNJ also had issues with its consumer segment manufacturing facilities. Another headwind is unfavorable currency movement.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 2.13%. Estimates have also been revised upwards for 2016.
Currently, JNJ has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on second quarter earnings - the company reported EPS of $1.74 while our consensus called for EPS of $1.67.
Revenues Beat: Revenues were above expectations as well. Johnson & Johnson posted revenues of $18.5 billion, compared to our consensus estimate of $17.9 billion.
Ups Guidance: J&J upped its 2016 sales guidance to $71.5 billion - $72.2 billion (guidance provided with 1Q results: $71.2 billion to $71.9 billion) and earnings guidance to $6.63 - $6.73 per share (guidance provided with 1Q results: $6.53 - $6.68 per share). The Zacks Consensus Estimate for revenues and earnings currently stands at $71.6 billion and $6.60 per share, respectively.
JOHNSON & JOHNS Price
JOHNSON & JOHNS Price | JOHNSON & JOHNS Quote
Pre-Market Trading: Shares were up more than 3% in pre-market trading.
Check back later for our full write up on this JNJ earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>